Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 12:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 41 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fibroblast Growth Factor 23 Clear all

Conditions: Phosphorus Metabolism
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS)
Interventions: Burosumab; Biological
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 7
States / cities: Golden, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 4 more

Conditions: Healthy
Interventions: Nicotinamide, Lanthanum Carbonate, Lanthanum Carbonate Placebo, Nicotinamide Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Solid Tumor
Interventions: Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range, Derazantinib at recommended phase 2 dose (RP2D); Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 8
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more

Conditions: X-Linked Hypophosphatemia
Interventions: KRN23; Biological
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more

Conditions: Chronic Kidney Disease
Interventions: grain (soy) protein diet, casein (meat) protein diet; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
Interventions: AL58805, AL3818, Temozolomide (TMZ), CCNU; Drug
Lead sponsor: Advenchen Pharmaceuticals, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Kidney Disease
Interventions: Lanthanum Carbonate, Low Phosphorus Diet, Unrestricted Phosphorus Diet, Placebo; Drug · Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: X-linked Hypophosphatemia
Interventions: burosumab, Placebo; Biological · Other
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 5 more

Conditions: Kidney Disease
Interventions: Lanthanum Carbonate, 900 mg Phosphate Diet, LC Placebo, Ad Libitum Diet; Drug · Other
Lead sponsor: Myles Wolf; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Vitamin D Deficiency
Interventions: Ergocalciferol, Ergocalciferol placebo; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tumor-Induced Osteomalacia, Oncogenic Osteomalacia
Interventions: BGJ398; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Kidney Disease
Interventions: K2CG chewing gum (20mg chitosan), K2CG chewing gum (60mg chitosan); Other
Lead sponsor: Denver Nephrologists, P.C.; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Tempe, Arizona • Denver, Colorado • Meridian, Idaho + 1 more

Conditions: Hypoparathyroidism
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy, Chronic Kidney Disease
Interventions: Diet; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Vitamin D Metabolism is in Chronic Kidney Disease
Interventions: 10,000 IU of cholecalciferol for a total of 8 weeks; Drug
Lead sponsor: Memphis VA Medical Center; Federal
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Vitamin D Deficiency, Cystic Fibrosis
Interventions: High-Dose Vitamin D3, Stool Sample, Sputum Sample, Sham Comparator, Blood draw; Dietary Supplement · Other · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Studying Phosphorus Metabolism

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Healthy Combine Study

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

Effect of Dietary Protein Source on Phosphaturia, PTH and FGF23 in Patients With CKD 3 and 4

A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)

Vitamin D Deficiency, Insulin Resistance and FGF-23

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease

Physiologic Regulation of FGF-23

Impact of Lowering Phosphate Additive Intake on Metabolism and Cardiovascular Health in Community-Living Adults

Vitamin D Metabolism in Chronic Kidney Disease Patients

Vitamin D and Microbiota in Cystic Fibrosis